Summit, Akeso Report Lung Cancer Survival Boost With Ivonescimab, A Rival To Merck's Keytruda Multi-Billion Dollar Franchise, Says Analyst

Summit Therapeutics Inc SMMT and Akeso said ivonescimab, a PD-1xVEGF bispecific antibody, can extend patients' lives for EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) progressed after EGFR-TKI treatment.Akeso said that the clinical trial’s final overall survival (OS) analysis showed that ivonescimab met the OS clinical endpoint.A "statistically significant and clinically meaningful" overall survival (OS) benefit has been observed in the final analysis of ivones ...